Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and Deoxyribonuclease (human clone protein moiety); Dornasa alfa. Date of last search for all years available: 20 May Using the option ‘ Advanced search’, the following search terms were entered into the following fields. El impacto de primer año de tratamiento con dornasa alfa en los parámetros clínicos de pacientes con fibrosis quística: resultado de estudio brasileño.
|Published (Last):||4 April 2004|
|PDF File Size:||2.78 Mb|
|ePub File Size:||10.35 Mb|
|Price:||Free* [*Free Regsitration Required]|
PULMOZYME INYECCIÓN 6 PIEZAS AMPOLLETA
Os pacientes foram acompanhados em cinco atendimentos ambulatoriais: Copyright and License information Disclaimer. The data on eligible patients, from 16 CF reference centers, that answered the medical questionnaires and performed laboratory tests at baseline T0and dognasa six T2 and 12 T4 months after dornase alfa initiation, were analyzed.
Delaying the decline in organ functions is one of the main goals of current treatments for CF, and initiation of dornase alfa early in the life is one of the identified factors associated with slower rate of decline in lung function Meda AB Medpointe Pharmaceuticals. In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections.
Pulmonary exacerbations are associated with subsequent Dprnasa decline in both adults and children with cystic fibrosis. Dornase alfa has recently been shown to improve lung function in non-cystic fibrosis pre-term infants atelectasis where other therapies have failed.
Received Nov 22; Accepted May Extracellular DNA is a viscous anionic polymer and its breakdown appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction.
Dornase Alfa: MedlinePlus Drug Information
DrugBank does not sell nor buy drugs. There was a significant reduction in the number of emergency room visits due to acute exacerbations when T4 was compared to T0. From Wikipedia, the free encyclopedia. There were no significant changes in forced expiratory volume in one second VEF 1in forced vital capacity FVCin oxygen saturation SpO 2and in Tiffenau index for all age groups.
Rajan S, Saiman L.
Incidence of cystic fibrosis in five different states of Brazil as determined by screening of p. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
A significant improvement in Shwachman-Kulczychi score was observed in the older group. Use dornase alfa exactly as directed.
In addition, a clinical stability questionnaire was used to evaluate the clinical conditions in the previous month A significant reduction in the number of emergency room visits due to acute exacerbations was coincident with improvement in the QoL Respiratory Domain of previous paper Author information Article notes Copyright and License information Disclaimer.
Part of these results was previously published Cystic alaf at a Brazilian center of excellence: In view of the current recommendations regarding the use of dornase alfa, it was decided not to have a control group, as the use of placebo or another mucolytic drug would be ethically questionable 5 Please help improve this article by adding citations to reliable sources.
It is dornaaa that an important aspect of CF evolution and prognosis is the rate of lung function decline, and slowing this rate is crucial for long-term survival The aim of this publication is to present additional information about the clinical profile of CF Brazilian patients after starting dornase alfa chronic use and to analyze their clinical parameters and patterns of care. Regarding patients’ characteristics, mean age at diagnosis was 9. Cystic fibrosis CF is a disease characterized by the retention of viscous purulent afla in the airways.
Health Qual Life Outcomes.
Dornase alfa – Wikipedia
The lack of a comparison group, not treated with dornase alfa, is a limitation that impairs a complete investigation about the benefits of the drug in CF patients. Dornase Alfa pronounced as door’ nace. Analysis of procedures performed in the daily routine, several times per day, including respiratory physical therapy, regular exercises, bronchodilators, oral and inhaled antibiotics, corticosteroids, dornase alfa, pancreatic enzymes and vitamins supplements, besides home oxygen and insulin in selected cases, showed that patients and their families are constantly occupied in performing time-consuming routines and complex treatment schedules imposed by the disease, and therefore, have limited time for leisure and a poor quality of life